α-fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid

Journal of Medicinal Chemistry

Volumn 52, Issue 8, 2009, Pages 2233-2242

  Pessah, Neta ^a   Bialer, Meir ^a,b   Wlodarczyk, Bogdan ^c   Finnell, Richard H ^c   Yagen, Boris ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BROMO 2,2,3,3 TETRAMETHYLCYCLOPROPANECARBOXAMIDE; 1 BROMO 2,2,3,3 TETRAMETHYLCYCLOPROPANECARBOXYLIC ACID; 1 CHLORO 2,2,3,3 TETRAMETHYLCYCLOPROPANECARBOXAMIDE; 1 CHLORO 2,2,3,3 TETRAMETHYLCYCLOPROPANECARBOXYLIC ACID; 1 FLUORO 2,2,3,3 TETRAMETHYLCYCLOPROPANECARBONYLUREA; 1 FLUORO 2,2,3,3 TETRAMETHYLCYCLOPROPANECARBOXAMIDE; 1 FLUORO 2,2,3,3 TETRAMETHYLCYCLOPROPANECARBOXYLIC ACID; 1 METHYL 2,2,3,3 TETRAMETHYLCYCLOPROPANECARBOXAMIDE; 1 METHYL 2,2,3,3 TETRAMETHYLCYCLOPROPANECARBOXYLIC ACID; N METHYL 1 FLUORO 2,2,3,3 TETRAMETHYLCYCLOPROPANECARBOXAMIDE; PILOCARPINE; UNCLASSIFIED DRUG; VALPROIC ACID; VALPROIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRIC SHOCK; EPILEPTIC STATE; EXPERIMENTAL MODEL; HIPPOCAMPUS; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; TEMPORAL LOBE EPILEPSY; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ANTICONVULSANTS; CYCLOPROPANES; EPILEPSY; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; VALPROIC ACID;

EID: 65249114616     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900017f     Document Type: Article

References (54)

1. Brodie, M. J.; Dichter, M. A. Antiepileptic Drugs. New. Engl. J. Med. 1996, 334, 168-175.
2. Bialer, M.; Walker, M. C; Josemir, W. S. Pros and Cons for the Develpment of New Antiepileptic Drugs. CNS Drugs 2002, 16, 285- 289.
3. Brodie, M. J. Do We Need Any More New Antiepileptic Drugs? Epilepsv Res. 2001, 45, 3-6.
4. Blaheta, R. A.; Nau, H.; Michaelis, M.; Cinatl, J., Jr. Valproate and Valproate-Analogues: Potent Tools To Fight against Cancer. Curr. Med. Chem. 2002, 9, 1417-1433.
5. Bourgeois, F. D. B. Valproic Acid: Clinical Efficacy and Use in Epilepsy. In Antiepileptic Drugs, 5th ed.; Levy, R. H., Mattson, R. H., Meldrum, B. S., Perucca, E., Eds.; Lippincott Williams and Wilkins Publishers: New York, 2002; pp 808-817.
6. Silberstein, D. S. Valproic Acid: Clinical Efficacy and Use in Other Neurological Disorders. In Antiepileptic Drugs, 5th ed.; Levy, R. H., Mattson, R. H., Meldrum, B. S., Perucca, E., Eds.; Lippincott Williams and Wilkins Publishers: New York, 2002; pp 818-827.
7. Swann, C. A. Valproic Acid: Clinical Efficacy and Use in Psychiatric Disorders. In Antiepileptic Drugs, 5th ed.; Levy, R. H., Mattson, R. H., Meldrum, B. S., Perucca, E., Eds.; Lippincott Williams and Wilkins Publishers: New York, 2002; pp 828-836.
8. Nau, H.; Hauck, R. S.; Ehlers, K. Valproic Acid-Induced Neural Tube Defects in Mouse and Human: Aspects of Chirality, Alternative Drug Development, Pharmacokinetics and Possible Mechanisms. Pharmacol. Toxicol. 1991, 69, 310-321.
9. Battino, D.; Tomson, T. Management of Epilepsy during Pregnancy. Drugs 2007, 67, 2727-2746.
10. Kaneko, S.; Battino, D.; Andermann, E.; Wada, K.; Kan, R.; Takeda, A.; Nakane, Y.; Ogawa, Y.; Avanzini, G.; Fumarola, C; Granata, T.; Molteni, F.; Pardi, G.; Minotti, L.; Canger, R.; Dansky, L.; Oguni, M.; Lopes-Cendas, I.; Sherwin, A.; Andermann, F.; Seni, M. H.; Okada, M.; Teranishi, T. Congenital Malformations Due to Antiepileptic Drugs. Epilepsy Res. 1999, 33, 145-158.
11. Koenig, S. A.; Buesing, D.; Longin, E.; Oehring, R.; Haussermann, P.; Kluger, G.; Lindmayer, F.; Hanusch, R.; Degen, I.; Kuhn, H.; Samii, K.; Jungck, A.; Bruckner, R.; Seitz, R.; Boxtermann, W.; Weber, Y.; Knapp, R.; Richard, H. H.; Weidner, B.; Kasper, J. M.; Haensch, C. A.; Fitzek, S.; Hartmann, M.; Borusiak, P.; Muller-Deile, A.; Degenhardt, V.; Korenke, G. C.; Hoppen, T.; Specht, U.; Gerstner, T. Valproic Acid-Induced Hepatopathy: Nine New Fatalities in Germany from 1994 to 2003. Epilepsia 2006, 47, 2027-2031.
12. Chang, T. K.; Abbott, F. S. Oxidative Stress as a Mechanism of Valproic Acid-Associated Hepatotoxicity. Drug Metgb Rev. 2006, 38, 627-639.
13. Bojic, U.; Ehlers, K.; Ellerbeck, U.; Bacon, C. L.; O'Driscoll, E.; O'Connell, C.; Berezin, V.; Kawa, A.; Lepekhin, E.; Bock, E.; Regan, C. M.; Nau, H. Studies on the Teratogen Pharmacophore of Valproic Acid Analogues: Evidence of Interactions at a Hydrophobic Centre. Eur. J. Pharmacol. 1998, 354, 289-299.
14. Bojic, U.; Elmazar, M. M. A.; Hauck, R.-S.; Nau, H. Further Branching of Valproate-Related Carboxylic Acids Reduces the Teratogenic Activity, but Not the Anticonvulsant Effect. Chem. Res. Toxicol. 1996, 9, 866-870.
15. Neuman, M. G.; Shear, N. H.; Jacobson-Brown, P. M.; Katz, G. G.; Neilson, H.; Malkiewicz, I. M.; Cameron, R. G.; Abbott, F. K. CYP2E1-Mediated Modulation of Valproic Acid-Induced Hepatocytotoxicity. Clin. Biochem. 2001, 34, 211-218.
16. Tang, W.; Borel, A. G.; Fujimiya, T.; Abbott, F. S. Fluorinated Analogs as Mechanistic Probes in Valproic Acid Hepatotoxicity: Hepatic Microvesicular Steatosis and Glutathione Status. Chem Res Toxicol 1995, 8, 671-682.
17. Tang, W.; Palaty, J.; Abbott, F. S. Time Course of Alpha-Fluorinated Valproic Acid in Mouse Brain and Serum and Its Effect on Synaptosomal Gamma-Aminobutyric Acid Levels in Comparison to Valproic Acid. J. Pharmacol. Exp. Ther. 1997, 282, 1163-1172.
18. Grillo, M. P.; Chiellini, G.; Tonelli, M.; Benet, L. Z. Effect of Alpha- Fluorination of Valproic Acid on Valproyl-S-acyl-CoA Formation in Vivo in Rats. Drug Metab. Dispos. 2001, 29, 1210-1215.
19. Loscher, W.; Nau, H. Pharmacological Evaluation of Various Metabolites and Analogues of Valproic Acid. Anticonvulsant and Toxic Potencies in Mice. Neuropharmacoloev 1985, 24, 427-435.
20. Morre, M.; Keane, P. E.; Vernieres, J. C.; Simiand, J.; Roncucci, R. Valproate: Recent Findings and Perspectives. Epilepsia 1984, 25, 5-9.
21. Hauck, R. S.; Nau, H. Asymmetric Synthesis and Enantioselective Teratogenicity of 2-n-Propyl-4-pentenoic Acid (4-en-VPA), an Active Metabolite of the Anticonvulsant Drug, Valproic Acid. Toxicol. Lett. 1989, 49, 41-48.
22. Hauck, R. S.; Nau, H. The Enantiomers of the Valproic Acid Analogue 2-n-Propyl-4-Pentynoic Acid (4-yn-VPA) : Asymmetric Synthesis and Highly Stereoselective Teratogenicity in Mice. Pharm. Res. 1992, 9, 850-855.
23. Isoherranen, N.; White, H. S.; Finnell, R. H.; Yagen, B.; Woodhead, J. H.; Bennett, G. D.; Wilcox, K. S.; Barton, M. E.; Bialer, M. Anticonvulsant Profile and Teratogenicity of N-Methyl-tetramethylcyclopropyl Carboxamide: A New Antiepileptic Drug. Epilepsia 2002, 43, 115-126.
24. Isoherranen, N.; Levy, R. H.; Yagen, B.; Woodhead, J. H.; White, H. S.; Bialer, M. Metabolism of a New Antiepileptic Drug, N-Methyl- Tetramethylcyclopropanecarboxamide, and Anticonvulsant Activity of Its Metabolites. Epilepsy Res. 2004, 58, 1-12.
25. Hadad, S.; Bialer, M. Pharmacokinetic Analysis and Antiepileptic Activity of N -Valproyl Derivatives of GABA and Glycine. Pharm. Res. 1995, 12, 905-910.
26. Haj-Yehia, A.; Bialer, M. Structure-Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepileptic Activity. Pharm. Res. 1989, 6, 683-689.
27. Shimshoni, J. A.; Bialer, M.; Wlodarczyk, B.; Finnell, R. H.; Yagen, B. Potent Anticonvulsant Urea Derivatives of Constitutional Isomers of Valproic Acid. J. Med. Chem. 2007, 50, 6419-6427.
28. Sobol, E.; Bialer, M.; Yagen, B. Tetramethylcyclopropyl Analogue of a Leading Antiepileptic Drug, Valproic Acid. Synthesis and Evaluation of Anticonvulsant Activity of Its Amide Derivatives. J. Med. Chem. 2004, 47, 4316-4326.
29. Gravemann, U.; Volland, J.; Nau, H. Hydroxamic Acid and Fluorinated Derivatives of Valproic Acid: Anticonvulsant Activity, Neurotoxicity and Teratogenicity. Neurotoxicol. Teratol. 2008, 30, 390-394.
30. Winkler, I.; Sobol, E.; Yagen, B.; Steinman, A.; Devor, M.; Bialer, M. Efficacy of Antiepileptic Tetramethylcyclopropyl Analogues of Valproic Acid Amides in a Rat Model of Neuropathic Pain. Neurop harmacoloev 2005, 49, 1110-1120.
31. Bialer, M.; Hadad, S.; Kadry, B.; Abdul-Hai, A.; Haj-Yehia, A.; Sterling, J.; Herzig, Y.; Yagen, B. Pharmacokinetic Analysis and Antiepileptic Activity of Tetra-Methylcyclopropane Analogues of Valpromide. Pharm. Res. 1996, 13, 284-289.
32. Shimshoni, J. A.; Bialer, M.; Yagen, B. Synthesis and Anticonvulsant Activity of Aromatic Tetramethylcyclopropanecarboxamide Derivatives. Bioorg med, Chem. 2008, 16, 6297-6305.
33. Okada, A.; Onishi, Y.; Aoki, Y.; Yagen, B.; Sobol, E.; Bialer, M.; Fujiwara, M. Teratology Study of Derivatives of Tetramethylcyclopropyl Amide Analogues of Valproic Acid in Mce. Birth Defects Res., Part B 2006, 77, 227-233.
34. Nau, H. Preparation of 2-Fluoro-2-alkylalkanoamide with Anticonvulsant and Antiepileptic Activity and Reduced Side Effects. PCT Int. Appl. WO 9967199, 1999.
35. Furniss, B. S.; Hannaford, A. J.; Smith, P. W. G.; Tatchell, A. R. Vogell's Textbook of Practical Organic Chemistry; Prentice Hall: New York, 1989; pp 695-670.
36. White, H. S.; Woodhead, J. H.; Wilcox, K. S.; Stables, J. P.; Kupferberg, H. J.; Wolf, H. H. Discovery and Preclinical Development of Antiepileptic Drugs. In Antiepileptic Drugs, 5th ed.; Levy, R. H., Mattson, R. H., Meldrum, B. S., Perucca, E., Eds.; Lippincott Williams and Wilkins Publishers: New York, 2002; pp 36-48.
37. Bialer, M. New Antiepileptic Drugs That Are Second Generation to Existing Antiepileptic Drugs. Expert Opin. InVest. Drugs 2006, 15, 637- 647.
38. Furniss, B. S.; Hannaford, A. J.; Smith, P. W. G.; Tatchell, A. R. Vogell's Textbook of Practical Organic Chemistry; Prentice Hall: New York, 1989; pp 719-724.
39. Zhang, L. H.; Duan, J.; Xu, Y.; Dolbier, W. R. J. A Simple and Efficient Method of Preparing Alpha-Bromo Carboxylic Acids. Tetrahedron Lett. 1998, 39, 9621-9622.
40. Hitchcock, S. A.; Houldsworth, S. J.; Pattenden, G.; Pryde, D. C.; Thomson, N. M.; Blake, A. J. A Tandem Radical Macrocyclization- Transannular Cyclization Approach towards the Taxanes. J Chem Soc. Perkin Trans. 1 1998, 3181-3206.
41. Hoffmann, H. M. R.; Wulff, J. M.; Kuetz, A.; Wartchow, R. Carbonylcyclopropanes (Cyclopropylidenemethanones) : Preparation and Stereochemistry of Cyclodimerization to Dispiro[2.1.2.1]octane- 4, 8-diones. Angew. Chem. 1982, 94, 79-80.
42. Goodman, J. H. Experimental Models of Status Epilepticus. In Neuropharmacology Methods in Epilepsy Research; Peterson, S. L., Albertson, T. E., Eds.; CRC Press: Boca Raton, FL, 1998; pp 95-125.
43. Chapman, M. G.; Smith, M.; Hirsch, N. P. Status epilepticus. Anaesthesia 2001, 56, 648-659.
44. Rosenow, F.; Arzimanoglou, A.; Baulac, M. Recent Developments in Treatment of Status Epilepticus: A Review. Epileptic Disord. 2002, 4 (Suppl. 2), S41-S51.
45. Barton, M. E.; Klein, B. D.; Wolf, H. H.; White, H. S. Pharmacological Characterization of the 6 Hz Psychomotor Seizure Model of Partial Epilepsy. Epilepsy Res. 2001, 47, 217-227.
46. Loscher, W.; Honack, D. Profile of ucb L059, a Novel Anticonvulsant Drug, in Models of Partial and Generalized Epilepsy in Mce and Rats. Eur. J. Pharmacol. 1993, 232, 147-158.
47. Fisher, R. S. Animal Models of the Epilepsies. Brain Res. Rev. 1989, 14, 245-278.
48. Loscher, W. Basic Pharmacology of Valproate. CNS Drugs 2002, 16, 669-694.
49. Tomson, T.; Battino, D. Teratogenic Effects of Antiepileptic Drugs. Seizure 2008, 17, 176-171.
50. Rogawski, M. A. Diverse Mechanism of Antiepileptic Drugs in the Development Pipeline. Epilepsy Res. 2008, 69, 273-294.
51. Schmidt, D.; Rogawski, M. A. New Strategies for the Identification of Drugs To Prevent the Development or Progression of Epilepsy. Epilepsy Res. 2002, 50, 71-78.
52. Bialer, M.; Yagen, B. Valproic Acid: Second Generation. Neurotherapeutics 2007, 4, 130-137.
53. Isoherranen, N.; White, H. S.; Klein, B. D.; Roeder, M.; Woodhead, J. H.; Schurig, V.; Yagen, B.; Bialer, M. Pharmacokinetic- Pharmacodynamic Relationships of (2S, 3S) -Valnoctamide and Its Stereoisomer (2R, 3S) -Valnoctamide in Rodent Models of Epilepsy. Pharm. Res. 2003, 20, 1293-1301.
54. Racine, R. J. Modification of Seizure Activity by Electrical Stimulation. II. Motor Seizure. Electroencephalogr. Clin. Neurophysiol. 1972, 32, 281-294. DOI: 10.1021/jm900028n